GSK to bring more innovative vaccines, medicines to Vietnam

GSK aims to positively impact the health of 2.5 billion people over the next 10 years. In Vietnam, how will this goal be accomplished?

For nearly three decades, GSK has contributed to preventing and treating diseases in the country with its medicines and vaccines. Looking forward, GSK aims to deliver positive health impacts to more than one-third of the Vietnamese population over the next three years.

To deliver on this ambition, GSK launched its new legal entity in Vietnam last year as GSK Pharma Vietnam Company Limited, or GSK Vietnam, with investment capital of $200 million. This demonstrates our strong commitment to long-term investment to help Vietnam keep pace with new innovations like other developed countries and ensure residents have access to prevention and treatment solutions whenever they need them.

How does GSK assess the potential of the Vietnamese market, which has seen people's care about their health and disposable income keep rising?

Vietnam is a promising emerging market with significant economic growth, an increasing population, rapid urbanization, and many other potentials.

GSK launched its new legal entity in Vietnam in 2022 by establishing a "good storage practices" (GSP) warehouse in Ho Chi Minh City, whereby medicines and vaccines are guaranteed to be of the highest quality and safety and meet Vietnamese and international standards.

On March 15, the UK Prime Minister’s Trade Envoy to Vietnam Mark Garnier visited the new warehouse during his first official visit to the nation. He was impressed by GSK’s operations in this world-class warehouse and congratulated GSK Vietnam for this achievement.

Thanks to the implementation of the UK-Vietnam Free Trade Agreement starting in 2021, trade collaboration between the two countries is significantly increasing, as reflected in more investments from British biopharmaceutical companies and more efforts to support Vietnamese people to have faster access to innovative prevention and treatment solutions.

Does this mean GSK will bring more innovative products to Vietnam?

Our plan is to assist healthcare professionals and patients in preventing and treating diseases by prioritizing innovation, performance, and trust. In terms of innovation, GSK aims to launch five new medicines and vaccines where they are needed to meet local disease patterns over five years. For performance, our ambitions for patients are reflected in our commitments to a step-change in growth, and more GSK vaccines and medicines will reach Vietnamese people.

We have long believed that being a responsible business and building trust is key to delivering our ambition for patients and society, and attracting outstanding people to work with us. We can only deliver on our purpose and build trust if we embed ESG, or environmental, social, and governance, into everything that we do; and in Vietnam, DEI (diversity, equity, inclusion), an ethical standard, and the environment are some of the areas we are prioritizing.

The culture at GSK is something we all own. It powers our purpose, drives the delivery of our strategy, and helps make GSK a place where people can thrive. Our culture of being ambitious for patients, accountable for impacts and doing the right thing is the foundation for how, together, we’ll deliver for our patients and GSK people.

What is GSK prioritizing in the Vietnamese market, where the population is 100 million?

GSK's priority is to make great efforts to give Vietnamese people access to the latest innovative medicines and vaccines, similar to what we have conducted in developed countries such as the United States, the United Kingdom, and Singapore, or even in emerging markets like Brazil and India.